Ketilept Prolong

Quetiapine fumarate, the active ingredient in Ketilept Prolong, is an atypical antipsychotic presented as an oral formulation for oral use. It is prescribed for schizophrenia, bipolar disorder and as adjunct therapy in major depressive disorder, targeting adult patients who require mood stabilization and psychosis control.

GNH USA supplies Ketilept Prolong as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketilept Prolong, an atypical antipsychotic, is employed across several psychiatric conditions:

- Schizophrenia: reduces hallucinations, delusions and other psychotic symptoms. - Bipolar disorder: stabilises mood during both manic and depressive episodes. - Major depressive disorder (adjunct): enhances the effect of standard antidepressants when added to therapy.

Ketilept Prolong may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Sedation or drowsiness - Dizziness or orthostatic hypotension - Dry mouth - Weight gain - Constipation - Increased appetite

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Agranulocytosis or severe leukopenia - QT interval prolongation and cardiac arrhythmias - Suicidal thoughts or behaviour - Severe hypotension - Hepatic injury or elevated liver enzymes

When prescribing Ketilept Prolong, clinicians should consider several safety measures.

- Monitor blood pressure: watch for orthostatic hypotension, especially at treatment initiation. - Assess metabolic parameters: track weight, glucose and lipid levels regularly. - Evaluate cardiac status: obtain baseline ECG and monitor QT interval in at‑risk patients. - Review concomitant CNS depressants: avoid excessive sedation when combined with alcohol or benzodiazepines. - Counsel on pregnancy and lactation: discuss limited data and potential risks with women of child‑bearing potential. - Store at room temperature: keep in the original container, protect from moisture and light.

Ketilept Prolong interacts with several drug classes; careful management is required.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise quetiapine plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower efficacy. - Other CNS depressants (alcohol, benzodiazepines): can intensify sedation and respiratory depression. - Antihypertensive agents: additive hypotensive effect may cause dizziness.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): increased risk of QT prolongation. - Antidiabetic drugs: quetiapine may affect glucose control; monitor blood sugar. - Lithium: combined use may raise neurotoxicity risk; observe serum levels.